Metriopharm
  • en
  • de
MetrioPharm AG
  • Home
  • About us
    • Our Company
    • Management and Board
    • Scientific Advisory Board
    • Career
  • Technology
    • MetrioPharm Platform
    • Mechanism of Action
    • Scientific Publications
  • Pipeline
    • Indication
    • Patent Protection
  • Investors
    • IR-News
    • Financial Report and Statutes
    • Annual General Meeting
  • Press
    • Press Releases
    • Corporate Calendar
  • Contact
    • Contact
    • Privacy policy
    • Imprint
  • en
  • de
  1. Home
  2. Investors
  3. Financial Report and Statutes

Financial Report and Statutes

 

MetrioPharm AG Annual Report 2023

MetrioPharm AG Annual Report 2023


Statutes

Statutes of MetrioPharm AG (November 2023, German only)

 

Investor Relations

Investor-Update QI 2025 - 2025-Apr-03

Extraordinary General Meeting of MetrioPharm AG, Save the Date: Annual General Meeting of MetrioPharm AG, Company Calendar 2025, MetrioPharm AG informs

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

 

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film

Newsletter Subscription

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Navigation

  • Home
  • About us
  • Technology
  • Pipeline
  • Investors
  • Press
  • Contact

Social

        

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Phone: +41 44 552 7190

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

  • © 2025 MetrioPharm AG
  • Imprint
  • Privacy policy (We don’t collect cookies)
  • Sitemap